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Ex vivo assessment and in vivo 
validation of non-invasive stent 
monitoring techniques based on 
microwave spectrometry
Carolina Gálvez-Montón1,2, Gianluca Arauz-Garofalo3, Oriol Rodriguez-Leor2,4,5, 
Carolina Soler-Botija1,2, Susana Amorós García de Valdecasas6, Flavio David Gerez-Britos3, 
Antoni Bayes-Genis1,2,4,5, Juan Manuel O’Callaghan  6, Ferran Macià  3 & Javier Tejada3
Some conditions are well known to be directly associated with stent failure, including in-stent re-
occlusion and stent fracture. Currently, identification of these high-risk conditions requires invasive 
and complex procedures. This study aims to assess microwave spectrometry (MWS) for monitoring 
stents non-invasively. Preliminary ex vivo data are presented to move to in vivo validation. Fifteen mice 
were assigned to receive subcutaneous stent implantations (n = 10) or sham operations (n = 5). MWS 
measurements were carried out at 0, 2, 4, 7, 14, 22, and 29 days of follow-up. Additionally, 5 stented 
animals were summited to micro-CT analyses at the same time points. At 29 days, 3 animals were 
included into a stent fracture subgroup and underwent a last MWS and micro-CT analysis. MWS was 
able to identify stent position and in-stent stenosis over time, also discerning significant differences 
from baseline measures (P < 0.001). Moreover, MWS identified fractured vs. non-fractured stents in 
vivo. Taken together, MWS emerges as a non-invasive, non-ionizing alternative for stent monitoring. 
MWS analysis clearly distinguished between in-stent stenosis and stent fracture phenomena.
Coronary artery disease is the leading cause of death worldwide. It contributes to more than 7 million deaths 
annually1. Percutaneous coronary intervention with stenting is the most widely performed procedure for the 
treatment of symptomatic coronary artery disease2. Although drug-eluting stents have minimized the limita-
tions of bare-metal stents, serious concerns remain about late complications, such as in-stent restenosis and late 
stent thrombosis3. Some conditions are known to be directly associated with stent failure, including in-stent 
neointimal proliferation, late malapposition related to positive vascular remodeling, stent fracture, and in-stent 
neoatherosclerosis4. Pre-clinical identification of these high-risk conditions requires invasive, complex proce-
dures, such as coronary angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), or 
multislice computed tomography5,6. Several high frequency-based alternatives for monitoring stents have been 
investigated7–9, but require complex solutions such as prior incorporation of electronic chips to the stent.
Recent studies have assessed the prospect of a new, non-invasive, non-ionizing stent monitoring method 
based on microwave spectrometry (MWS)10–12. In contrast to the other approaches, MWS does not require prior 
stent modifications and should be valid with all currently available metallic stents.
In this context, MWS -defined as a measurement of the frequency response of the sample to microwave elec-
tromagnetic fields- is a potentially non-invasive and non-ionizing stent monitoring technique. The principle of 
the MWS technique relies on the interaction between an electromagnetic wave and an object with high conduc-
tivity, such as a metallic stent. Similar to a tuning fork that resonates at particular sound frequencies, the electrons 
from the stent alloy establish standing waves of current that resonate at microwave frequencies10,11. From the 
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characteristic resonance frequencies of the stent, we can obtain information about the stent status. In this work 
we have set up a new approach for detection of stent structural failure and in-stent lipid occlusion, and thus, for 
the first time, we assessed in vivo MWS for stent monitoring.
Methods
A detailed description is provided in the Supplementary Material.
In vitro stent testing. The in vitro methods of the present work comprise three tests in which a commercial 
coronary stent (see Supplementary Table 1 for details) is submitted to different processes to emulate common 
stent-related complications: stent fracture, diametrical stent collapse (recoil), and neointimal atherosclerotic 
transformation inside a stent (in-stent lipid occlusion).
Stent fracture test. Once expanded, the stent length (ℓAB) was measured using an IP67 digital caliper (Vogel 
Germany GmbH & Co., Kevelaer, Nordrhein-Westfalen, Germany) and its A(f, ϕ) chart was acquired. Next, we 
split the stent into two segments by cutting the weld linking two adjacent crowns with customized scissors, which 
led to a grade III fracture12. The lengths (ℓA and ℓB) of the resulting segments were also measured. The A(f, ϕ) 
chart for the fractured stent was acquired by placing both segments 1 mm apart on the sample holder.
Stent recoil test. To simulate recoil, we smoothly changed the stent diameter along a wide range of values. The 
variations were progressive and uniform along the entire length of the stent. The pressure of the balloon catheter, 
p, was increased in a stepwise manner. At each stage, the A(f, ϕ) chart and diameter of the stent, d, were measured 
using an IP65 digital micrometer (Vogel Germany GmbH & Co., Kevelaer, Nordrhein-Westfalen, Germany).
In-stent lipid occlusion test. Once expansion of the stent was completed, it was subjected to progressive choles-
terol deposition to simulate worsening in-stent lipid occlusion. The cholesterol deposition process was carried out 
by spraying the stent with a cholesterol-saturated (94%, Sigma-Aldrich) ethanol (96%, Panreac) solution.
Murine animal model and in vivo micro-CT analysis. Animal studies were approved by the Germans 
Trias i Pujol Research Institute Animal Experimentation Ethics Committee (B9900005) and the Generalitat de 
Catalunya government (DARP: 8688),  and complied with the Guide for the Care and Use of Laboratory Animals 
(NIH Publication No. 8023, revised 1996). Eleven bare-metal stents (Stent Architect, 4.00 mm diameter, 19 mm 
length; iVascular, S.L.U) were used. Ten were implanted in mice, and one was characterized in open-air condi-
tions, as a reference. Fifteen C57/Bl6 female mice (18 ± 1 g; 10 weeks old; Harlan Laboratories, SA.) were ran-
domly distributed into: (1) experimental group (n = 10) with stent implantation, and (2) sham group (n = 5) with 
simulated stent implantation. Briefly, animals were anesthetized with a mixture of O2/isoflurane. Buprenorphine 
(0.1–0.5 mg/kg) was administered subcutaneously, as intraoperative analgesia. Next, after a paravertebral incision, 
a subcutaneous tunneling was performed to place the stent at 7.0 ± 0.5 atm. Finally, the surgical wound was closed 
with cyanocryolate glue (3M TM Vetbond TM Tissue Adhesive, 3M), and animals were recovered.
Baseline MWS measurements were carried out after stent grafting (Day 0). Further measurements were done 
at 2, 4, 7, 14, 22, and 29 days. Additionally, 5 animals were submitted to micro-CT (Skyscan 1076 high resolution 
in vivo scanner, Kontich) analysis at the same time points, to detect deformations and stent breakage over time 
(Fig. 1A). Imaging was performed with gating for respiratory motion, and scan parameters were optimized to 
reduce scanning time and radiation dose. The radiation scan was applied with 45 kV source voltage and 250 µA, 
18 µm isotopic resolution, one projection image per 0° gantry rotation, rotation range 180°, and a field of view 
covering the thorax region. A titanium filter was used. The total standard acquisition time was 15 min.
At the end of the study, 3 of these 5 animals were submitted to stent fracture. Fractures were produced by mak-
ing a transverse cut in the stent, mimicking a type III fracture according to Allie-Jaff classification12. Cuts were 
made at different sites on the 3 stents (1/2, 1/4, and 1/5 of the stent length). Then, final MWS scan and micro-CT 
analyses were performed. Finally, animals were sacrificed with an overdose of anesthesia and stents were removed 
and photographed.
In vivo microwave spectrometry setup. It consisted of a two-port probe connected to a vector network 
analyzer (E8361A, Keysight Technologies) via coaxial feed lines (3GW40-0TD01D02048.0, W. L. Gore & 
Associates) (Fig. 1B). The probe was used to launch a microwave electromagnetic excitation onto the stent and to 
capture its response. To ensure that the microwave electromagnetic fields did not affect the biological tissues and 
conformed to the restrictions set in13, we performed a Finite Element Method (FEM) simulation using commer-
cial software (ANSYS HFSS). The parameters of the biological tissues used in the simulation (relative permittivity 
r  and conductivity σ) where measured using a commercial device (85070E dielectric probe kit, Keysight). The 
simulation was run on a 5 mm thick slab of material with  = 52r  and σ = 1 S/m and showed that, with the micro-
wave power used in the experiments (1 mW), the Specific Absorption Rate (SAR)13 was negligible everywhere 
except in a small region near the probe with a depth under 2 mm and a perimeter of 4.1 mm. The maximum SAR 
in that region was 6.6 W/kg, below the 10 W/kg limitation set for occupational exposure in13.
The transmission spectrum (TS) was acquired with our probe in a frequency range of 0.1 to 6.0 GHz, to iden-
tify the resonance frequencies characteristic of a stent implanted in mice.
Measurements were performed with anesthetized mice lying in a prone position on a padded surface, and their 
backs were palpated with the MWS probe. Ultrasound transmission gel (Aquasonic 100, Parker Laboratories, 
Inc.) was applied on the probe head to soften the medium transitions and convey microwaves without crossing 
air. Each experimental mouse characterization comprised 3 measurements at different scanning zones. The first 2 
zones were both with the probe centered above the stent, one parallel and the other angled at 30° with respect to 
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the stent axis. The third zone was shifted 10 mm to the right of the paravertebral position. Sham mouse character-
izations comprised the same 3 measurements.
Statistical Analysis. Differences in MWS analyses over time were evaluated with ANOVA for repeated 
measures and the Greenhouse correction, when Mauchly sphericity was not achieved. Data are presented as the 
mean ± standard deviation, and statistical significance was defined as P < 0.05.
The datasets generated and/or analyzed during the current study are available from the corresponding author 
on reasonable request.
Results
Ex vivo Analysis. Microwave spectrometry absorbance charts. Figure 2A presents the A(f, ϕ) chart for the 
stent used in fracture test to illustrate a typical MWS characterization. Each isoangular projection in this chart 
(horizontal line) represents the absorbance spectrum for a given ϕ value. Figure 2A shows the isoangular profiles 
at ϕ = 90°, 45°, and 0°. Note how the isoangular projection at ϕ = 90°shows a resonance (maximum absorbance), 
the precise frequency value of which can be extracted by applying fitting tools (f1 = 2.306 ± 0.004 GHz). This 
resonance is observed again with the isoangular projection at ϕ = 45°, but with a reduced amplitude. In this same 
ϕ = 45° isoangular projection, we detected an f2 of 4.317 ± 0.004 GHz, which was not present at ϕ = 90°. Finally, 
we observed that these two resonances eventually disappeared at ϕ = 0°.
Stent fracture test. Figure 2B summarizes the fracture test by comparing the two A(f, ϕ) charts taken before 
and after applying the cut. The fundamental resonance of the original stent (segment AB) is easily spotted in 
this chart (f1AB = 2.306 ± 0.004 GHz). The A(f, ϕ) chart of segments A and B placed together as described above 
is also included. As notable result, there is no trace of the original f1AB in this new chart. Instead, a pair of new 
Figure 1. Sketch of the MWS setup. (A) Representative micro-CT images display the location of the stent. (B) 
The network analyzer (a) sends an electromagnetic stimulus to the MWS probe (b) through a coaxial feedline 
(c). The generated microwave signal travels through mouse tissue, until it interacts with the stent. The emerging 
signal is collected by the MWS probe and sent back to the network analyzer via a second feedline (d). The figure 
was designed and hand-drawn by Carolina Gálvez-Montón. Cr = Cranial; Cd = Caudal; L = Left; R = Right; 
D = Dorsal; V = Ventral.
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resonances (f1A = 3.404 ± 0.008 GHz and f1B = 4.766 ± 0.012 GHz) appear at higher frequencies. The lengths of 
the intact segment AB and segments A and B resulting from the cut are 30.74 ± 0.08 mm, 18.58 ± 0.05 mm, and 
12.16 ± 0.03 mm, respectively.
Stent recoil test. Using non-invasive MWS we were able to identify a gradual up-shift of stent resonances as the 
stent diameter was reduced. After the recoil test carried out on the MER_1500_300 stent, MWS measurements 
displayed the A(f, ϕ) chart for the stent in the absence of recoil (r = 0.0 ± 0.1%), and the A(f, ϕ) charts for increas-
ing recoil degrees (r = 12.3 ± 1.0%, 22.7 ± 1.1%, and 37.6 ± 1.7%, respectively). Figure 2C provides the full view 
of the process by plotting the evolution of f1 and f2 as r increases. Finally, the micropictures shown in Fig. 2C show 
the stent at the extreme diameter values, dM and dm, used to define the recoil degree (see Supplementary Material).
In-stent lipid occlusion test. Figure 2D shows how MWS is able to detect the amount of cholesterol deposited on 
the stent by monitoring the absorbance resonance at ϕ = 90°. There is an important frequency downshift as cho-
lesterol mass accumulates on the stent, with a maximum downshift of 6.70 ± 0.14%. Figure 2D (Bottom) presents 
a sequence of six axial micropictures showing the progress of the cholesterol crust.
In vivo validation. Stent detection with MWS. Comparisons of the MWS signals acquired from experi-
mental and sham animals allowed us to establish the stent presence and location. Figure 3 illustrates the stent 
presence indicators provided by MWS performed on the 29th follow-up day. The red, green and blue areas on the 
Figure 2. Ex vivo tracking stent status with MWS. (A) Image displaying a typical MWS stent scan. 
(Left) Absorbance chart as a function of the MW frequency and scanning angle (A(f, ϕ)) of a Medtronic 
Endeavor Sprint DES (30 × 2.50 mm). (Right) Isoangular projections of the A(f, ϕ) chart at ϕ = 90°, 
45°, and 0°. (B) Fracture test performed on a Medtronic Endeavor Sprint stent (30 × 2.50 mm). The 
stent (AB) (length 30.74 ± 0.08 mm) is split into two segments (18.58 ± 0.05 mm and 12.16 ± 0.03 mm.; 
A and B) The original resonance (2.306 ± 0.004 GHz) (top right) splits into two resonant frequencies 
(3.404 ± 0.008 GHz and 4.766 ± 0.012 GHz) (bottom right). (C) Recoil test performed on a Medtronic 
Endeavor Resolute stent (15 × 3.00 mm). Absorbance chart for the stent at its maximum diameter (minimum 
recoil) (dM = 3.964 ± 0.013 mm, r = 0.0 ± 0.1%) (Left) and absorbance charts with decreasing diameter 
(d = 3.624 ± 0.013 mm; 3.333 ± 0.015 mm; and 2.92 ± 0.03 mm). (Top Right) Graphical evolution of the first two 
resonant frequencies, f1 and f2, for decreasing diameter (increasing recoil degree). (Bottom Right) Representative 
images showing the maximum and minimum diameters (dM and dm) used as references to define the recoil 
degree. (D) In-stent neoatherosclerosis test performed on a Medtronic Driver Sprint BMS (12 × 2.75 mm). 
(Top Left) Stent isoangular spectra at ϕ = 90° at each stage reached during the test, showing the shape of its 
fundamental resonance and a global downshift. (Top Right) Evolution of the fundamental resonant frequency 
with an increasing cholesterol depot, f1(m). (Bottom) Axial sequential imaging illustrates the evolution of the 
cholesterol crust (from left to right: m = 0.0 ± 0.5 mg, 3.5 ± 0.5 mg, 10.5 ± 0.5 mg, 15.0 ± 0.5 mg, 20.5 ± 0.5 mg, 
and 0.0 ± 0.5 mg). A = Absorbance; d = Diameter; dM = Maximum diameter; dm = Minimum diameter; 
dB = Decibels; f = Microwave frequency; GHz = Gigahertz; ϕ = Angle.
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mice contours in Fig. 3 indicate the position of the probe. Note that maximum signal is obtained when the probe 
is aligned with the stent and directly above it. The transmission spectrum (TS) obtained in experimental animals 
was compared to that acquired in sham animals. The spectra acquired from the stented animals showed remark-
ably larger signals than those acquired from the sham animals, even when the spectra from stented animals were 
acquired angling the probe (green curve). Furthermore, the stented animals displayed a resonance frequency that 
produced a shoulder-shaped feature in the spectra at f = 0.82 ± 0.10 GHz (red and green arrows), which was not 
present in either the blue spectrum or the 3 spectra measured in sham mice. Figure 3 shows representative data 
measured on a single day; analogous results were obtained for all animals during the entire monitoring period. 
All mice from the experimental group exhibited a characteristic shoulder-shaped resonance each day they were 
monitored, and no mice from the sham group ever displayed that feature.
In-stent stenosis. After performing the MWS measurements, we normalized all resonance frequencies for the 
experimental group (Table 1) to the resonance value of the first day (Day 0):
Δ =
−
f
f f
fmice
0
0
The statistical analysis indicated that significant changes occurred over time (P < 0.001). These results sug-
gested that in-stent stenosis could be detected based on the resonance frequency displacement Δfmice over time 
(Fig. 4). Note that the average resonance frequency rapidly shifted up, during the first 4 monitoring days, and then 
it stabilized at a relative displacement of approximately 16%.
Figure 3. In vivo detection of the stent by MWS. Transmission spectra (TS) acquired in animals with implanted 
stents (A) and with sham implantations (B) on the 29th follow-up day. Different colors represent distinct 
scanning positions for the microwave spectrometry (MWS) probe, with respect to the implantation zone 
(experimental group) or the simulated stent implantation zone (sham group). Red and green spectra of stented 
animals show a distinctive, shoulder-shaped signal, which is not present in either the blue spectrum (red and 
green arrows) or the three spectra measured in the sham mouse. TS = Transmission Spectrum; dB = Decibels 
f = Microwave frequency, GHz = Gigahertzs; MWS = Microwave Spectometry.
Animal Day 0 Day 2 Day 4 Day 7 Day 14 Day 22 Day29
M01 0.80 ± 0.20 0.76 ± 0.16 0.79 ± 0.08 0.76 ± 0.14 0.83 ± 0.09 0.79 ± 0.09 0.81 ± 0.09
M02 0.70 ± 0.08 0.79 ± 0.15 0.75 ± 0.09 0.75 ± 0.11 0.72 ± 0.09 0.76 ± 0.08 0.80 ± 0.10
M03 0.67 ± 0.11 0.76 ± 0.12 0.78 ± 0.10 0.79 ± 0.10 0.78 ± 0.12 0.76 ± 0.09 0.78 ± 0.09
M04 0.97 ± 0.10 0.76 ± 0.12 0.81 ± 0.10 0.78 ± 0.10 0.78 ± 0.08 0.78 ± 0.09 0.83 ± 0.12
M05 0.65 ± 0.07 0.81 ± 0.13 0.79 ± 0.09 0.83 ± 0.09 0.82 ± 0.10 0.76 ± 0.09 0.80 ± 0.11
M06 0.72 ± 0.18 0.76 ± 0.10 0.79 ± 0.11 0.77 ± 0.07 0.78 ± 0.11 0.84 ± 0.10 0.82 ± 0.10
M07 0.65 ± 0.07 0.68 ± 0.19 0.79 ± 0.13 0.74 ± 0.10 0.84 ± 0.10 0.82 ± 0.09 0.78 ± 0.08
M08 0.68 ± 0.06 0.74 ± 0.10 0.80 ± 0.11 0.81 ± 0.08 0.79 ± 0.09 0.81 ± 0.10 0.81 ± 0.11
M09 0.70 ± 0.08 0.76 ± 0.12 0.80 ± 0.10 0.84 ± 0.10 0.78 ± 0.09 0.79 ± 0.10 0.79 ± 0.10
M10 0.64 ± 0.08 0.79 ± 0.10 0.81 ± 0.09 0.79 ± 0.10 0.76 ± 0.09 0.77 ± 0.10 0.78 ± 0.10
Table 1. Resonance frequencies acquired with microwave spectrometry in mice with implanted stents.
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Stent fracture. To detect stent fractures with MWS, we measured the TS obtained before and after cutting 
the implanted stents into two segments (with short fragments of 1/2, 1/4, and 1/5 of the stent length) (n = 3). 
Figure 5 displays the results for the cuts performed at different locations along the stent shaft (see corre-
sponding pictograms and associated micro-photographs for details). In all 3 cases, the TSs were acquired on 
day 29. The characteristic shoulder-shaped resonance signals found before splitting the stent, at frequencies of 
fS1/2 = 0.78 ± 0.08 GHz, fS1/4 = 0.81 ± 0.11 GHz, and fS1/5 = 0.79 ± 0.10 GHz, were lost after the stents were fractured 
(black arrows).
Quantitative analysis of the stent resonance frequency. The resonant frequency for the stents implanted in mice 
(fmice) is consistent with that of the stent measured in air (fair) and the relative permittivity measurements of the 
tissue where the stents are implanted (εmice). Since the in vivo and open-air wavelengths at resonance are equal, we 
can extrapolate the open-air resonance frequency with in vivo data:
ε= ⋅f fair mice mice
Since fmice = 0.77 GHz and εmice is about 47 at that frequency (see Supplementary Fig. 2), the open-air resonance 
(fair) should be 5.28 GHz. This compares well with the measured value of fair (5.07 GHz) and the error margins in 
the permittivity measurements.
Figure 4. In vivo temporal evolution of stent resonance. (A) Graphic represents the relative displacement of 
the average resonance frequency (Δfmice) over time, for experimental mice (n = 10). (B) Images of implanted 
stents acquired before implantation (top), after sacrifice at 29 days of follow-up (middle), and after a NaOH wash 
(bottom). Δfmice = Average resonance frequency; t = Time.
Figure 5. In vivo comparison before and after fracturing the stent. The transmission sprectrum (TS) acquired 
before (solid lines) and after (dashed lines) cutting the stent. In all cases, the scanning position of the microwave 
spectrometry (MWS) probe was just above the stent, parallel to the direction of implantation. Each stent was 
broken in two segments, which left fragments that were about (A) 1/2, (B) 1/4, and (C) 1/5 of the stent length. 
See corresponding sketches of mice and the associated micro-pictures. dB = Decibels; f = Microwave frequency, 
GHz = Gigahertzs; TS = Transmission spectrum.
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Discussion
Late stent failure represents an unresolved issue in interventional cardiology. To date, after stent implantation, 
coronary stent evaluation requires repeated coronary angiography. Other invasive coronary imaging techniques, 
such as IVUS or OCT, offer information about the stent, the vessel lumen, the vessel wall, and the plaque bur-
den14. Nevertheless, IVUS and OCT are of limited use, because both techniques are invasive, expensive, and 
require hospital admission and a trained physician. A non-invasive methodology that could be implemented by 
non-specialized physicians to stratify the risk of patients after stent implantation would avoid these drawbacks.
In this context, the present study shows that MWS provides distinctive indicators for a variety of dif-
ferent changes in stent structure and environment ex vivo. On the one hand, MWS reveals stent fracture as a 
split-and-up-shift of the stent resonant frequency. On the second hand, stent recoil is shown as a gradual up-shift 
of the stent resonant frequency. The higher the diametrical shrinkage of the stent is, the larger the up-shift will 
be. Finally, MWS reveals cholesterol presence around stent as a downshift of its resonant frequency. A larger 
frequency shift corresponds to a higher cholesterol mass deposited on the stent. We expect this dependence to be 
even more sensitive in an in vivo measurement, where the ratio of permittivities of the materials involved (blood 
vs. cholesterol) would be higher than the one in our experiment (cholesterol vs. air). These ex vivo pre-clinical 
findings suggests us that this technology has the potential to monitor common concerns associated with cor-
onary stents over the long-term, which are changes in stent geometry (stent fracture and recoil) and in-stent 
re-occlusion (in-stent restenosis or in-stent lipid occlusion).
In our in vivo validation, comparison of TS spectra between experimental and sham groups showed that MWS 
provided two indicators of stent presence. First, the level of the TS spectra was enhanced when the probe was accu-
rately aligned with the stent (compare red and blue solid lines in Fig. 3A); this suggested the possibility of using 
MWS for determining stent position. Second, the presence of the stent produced a characteristic shoulder-shaped 
resonance at f = 0.82 ± 0.10 GHz (see red arrow in Fig. 3A). Note that the TS peaks at around 1.4 GHz that appeared 
in all experimental conditions were related to the probe design and had no significance in stent monitoring.
We used the MWS formal framework10 and independent permittivity measurements11,14 to check the agree-
ment between open-air and in vivo resonance frequencies ( ε= ⋅f fair mice mice). This fact confirmed that the 
shoulder-shaped resonance in the in vivo measurements (Fig. 3A) was actually due to the presence of the stent.
Late-acquired stent malapposition or stent recoil is a well-recognized problem in interventional cardiology 
because it may give rise to late stent thrombosis, and the subsequent need for prolonging dual antiplatelet therapy. 
The incidence of late-acquired stent malapposition was reported to be as high as 25% in patients with acute myo-
cardial infarction12,15. In this context, we also evaluated in vivo the in-stent stenosis with the MWS system. The 
evolution of the average resonance frequency showed that stents experienced notable alterations during the first 
4 days after implantation, and then eventually stabilized on the fifth day. It is well known that stent resonance fre-
quencies strongly depend on the dielectric permittivity of the surrounding medium10,11,14. This physical property 
of matter can be understood as the opposition encountered by an electric field, when it forms within a medium, 
such as a biological tissue. Because different tissues present distinct characteristic dielectric permittivity profiles16, 
the upward shift in the average resonance frequency we observed (Fig. 4A) could be assigned to tissue remodeling 
around the implanted stent (interested readers can refer to the Supplementary Material for an extended argumen-
tation). Mouse post-mortem autopsies showed that the interstitial fluid in the stent lumen just after subcutaneous 
stent implant was gradually replaced by fibrotic tissue (Fig. 4B). This fibrotic phenomenon was also previously 
described in bare-metal stents that were subcutaneously implanted in rats17. Moreover, our implanted stents had 
adhered to the surrounding tissues, and those tissues penetrated into the stent and caused tissue proliferation 
mimicking in-stent stenosis. As we have demonstrated, the MWS system indicated in-stent fibrotic formations 
and depositions that took place during the early days of follow-up in all experimental animals. Thus, MWS might 
offer a new option of monitoring to discern which patients are at high risk of in-stent stenosis.
Stent fracture is a late complication of stent implantation, but its true incidence remains unknown. However, 
rates up to 29% have been reported. Patients with stent fractures may remain asymptomatic, but they may present 
acute coronary syndrome, stent thrombosis, or recurrent angina due to clinical restenosis. Overall, 70% to 80% of 
patients with a stent fracture will present in-stent restenosis or stent thrombosis18,19. Using MWS we were able to 
identify changes exhibited by the A(f, ϕ) chart after fracturing the stent, specifically split in the original resonance 
producing two new higher frequencies. Furthermore, we successfully showed that f1A is unequivocally due to 
segment A just by measuring its A(f, ϕ) separately. We also checked that f1B was unequivocally due to segment B. 
Additionally, since the fundamental mechanism behind this split-and-shift-up behavior is well understood, the 
quantitative evaluation of grade III (and even grade IV) stent fractures is possible11.
Taken together, our results have opened up a new paradigm in stent monitoring. Although further studies in 
large animal models are needed to validate the present results, this study showed that MWS methodology could 
allow non-invasive, non-ionizing coronary stent monitoring for diagnosing different conditions related to stent 
failure at a pre-clinical stage.
Study limitations. The present study described a new methodology for monitoring the status of implanted 
stents. With MWS analysis, we detected the presence of the stent, in-stent restenosis, and type III stent fractures. 
Further studies are needed to discern materials of different natures, such lipidic, thrombotic, and fibrin deposits. 
Moreover, different types of stent fractures should be evaluated.
Conclusions
This study described a new MWS system, which offers, for the first time, the potential of detecting the presence of 
implanted stents in mice and monitoring stent restenosis and fractures. Moreover, this novel, probe-based, non-invasive, 
non-ionizing methodology would not require sedation, patient hospitalization, or specialized physicians. This data rep-
resented a proof-of-principle for the MWS approach, a valuable step before undertaking clinical translation.
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